{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:07:57Z","timestamp":1764997677369,"version":"3.41.2"},"reference-count":60,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,7,18]]},"DOI":"10.1248\/bpb.b25-00250","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T22:07:56Z","timestamp":1752790076000},"page":"1040-1048","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological Inhibition of ROR&lt;i&gt;\u03b3&lt;\/i&gt; Ameliorates Skin Inflammation Induced by Both Antigen- and Cytokine-Activated Th17 Cells"],"prefix":"10.1248","volume":"48","author":[{"given":"Kojo","family":"Arita","sequence":"first","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Tajima","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kemmochi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u201313\u20132 Fukuura, Kanazawa-ku, Yokohama 236\u20130004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Katsuda","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Konishi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Egawa G, Kabashima K. Skin as a peripheral lymphoid organ: revisiting the concept of skin-associated lymphoid tissues. <i>J. Invest. Dermatol.<\/i>, <b>131<\/b>, 2178\u20132185 (2011).","DOI":"10.1038\/jid.2011.198"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nomura T, Kabashima K, Miyachi Y. The panoply of <i>\u03b1\u03b2<\/i>T cells in the skin. <i>J. Dermatol. Sci.<\/i>, <b>76<\/b>, 3\u20139 (2014).","DOI":"10.1016\/j.jdermsci.2014.07.010"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. <i>Dermatol. Ther.<\/i>, <b>21<\/b>, 54\u201359 (2008).","DOI":"10.1111\/j.1529-8019.2008.00170.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. <i>J. Am. Acad. Dermatol.<\/i>, <b>41<\/b>, 401\u2013407 (1999).","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. <i>Immunol. Today<\/i>, <b>17<\/b>, 138\u2013146 (1996).","DOI":"10.1016\/0167-5699(96)80606-2"},{"key":"6","unstructured":"6) Kidd P. Th1\/Th2 balance: the hypothesis, its limitations, and implications for health and disease. <i>Altern. Med. Rev.<\/i>, <b>8<\/b>, 223\u2013246 (2003)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4<sup>+<\/sup> effector T cells develop <i>via<\/i> a lineage distinct from the T helper type 1 and 2 lineages. <i>Nat. Immunol.<\/i>, <b>6<\/b>, 1123\u20131132 (2005).","DOI":"10.1038\/ni1254"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. <i>Nat. Immunol.<\/i>, <b>6<\/b>, 1133\u20131141 (2005).","DOI":"10.1038\/ni1261"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. <i>Nature<\/i>, <b>441<\/b>, 235\u2013238 (2006).","DOI":"10.1038\/nature04753"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Mangan PR, Harrington LE, O\u2019Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-<i>\u03b2<\/i> induces development of the T<sub>H<\/sub>17 lineage. <i>Nature<\/i>, <b>441<\/b>, 231\u2013234 (2006).","DOI":"10.1038\/nature04754"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. <i>Annu. Rev. Immunol.<\/i>, <b>27<\/b>, 485\u2013517 (2009).","DOI":"10.1146\/annurev.immunol.021908.132710"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. <i>J. Exp. Med.<\/i>, <b>201<\/b>, 233\u2013240 (2005).","DOI":"10.1084\/jem.20041257"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor ROR<i>\u03b3<\/i>t directs the differentiation program of proinflammatory IL-17<sup>+<\/sup> T helper cells. <i>Cell<\/i>, <b>126<\/b>, 1121\u20131133 (2006).","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. <i>Br. J. Dermatol.<\/i>, <b>160<\/b>, 319\u2013324 (2009).","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. <i>J. Invest. Dermatol.<\/i>, <b>128<\/b>, 1207\u20131211 (2008).","DOI":"10.1038\/sj.jid.5701213"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. <i>J. Immunol.<\/i>, <b>186<\/b>, 1495\u20131502 (2011).","DOI":"10.4049\/jimmunol.1001001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated <i>via<\/i> the IL-23\/IL-17 axis. <i>J. Immunol.<\/i>, <b>182<\/b>, 5836\u20135845 (2009).","DOI":"10.4049\/jimmunol.0802999"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. <i>J. Immunol.<\/i>, <b>188<\/b>, 462\u2013469 (2012).","DOI":"10.4049\/jimmunol.1102224"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet<\/i>, <b>371<\/b>, 1665\u20131674 (2008).","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. <i>N. Engl. J. Med.<\/i>, <b>375<\/b>, 345\u2013356 (2016).","DOI":"10.1056\/NEJMoa1512711"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. <i>N. Engl. J. Med.<\/i>, <b>371<\/b>, 326\u2013338 (2014).","DOI":"10.1056\/NEJMoa1314258"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <i>Lancet<\/i>, <b>371<\/b>, 1675\u20131684 (2008).","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"23","unstructured":"23) World Health Organization. <i>Global Report on Psoriasis<\/i>. World Health Organization, Geneve (2016)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Jones DA, Yawalkar N, Suh KY, Sadat S, Rich B, Kupper TS. Identification of autoantigens in psoriatic plaques using expression cloning. <i>J. Invest. Dermatol.<\/i>, <b>123<\/b>, 93\u2013100 (2004).","DOI":"10.1111\/j.0022-202X.2004.22709.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nat. Commun.<\/i>, <b>5<\/b>, 5621 (2014).","DOI":"10.1038\/ncomms6621"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR. Digoxin and its derivatives suppress Th17 cell differentiation by antagonizing ROR<i>\u03b3<\/i>t activity. <i>Nature<\/i>, <b>472<\/b>, 486\u2013490 (2011).","DOI":"10.1038\/nature09978"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovi\u0107 D, Sch\u00fcrer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP. Suppression of Th17 differentiation and autoimmunity by a synthetic ROR ligand. <i>Nature<\/i>, <b>472<\/b>, 491\u2013494 (2011).","DOI":"10.1038\/nature10075"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Banerjee D, Zhao L, Wu L, Palanichamy A, Ergun A, Peng L, Quigley C, Hamann S, Dunstan R, Cullen P, Allaire N, Guertin K, Wang T, Chao J, Loh C, Fontenot JD. Small molecule mediated inhibition of ROR<i>\u03b3<\/i>-dependent gene expression and autoimmune disease pathology <i>in vivo<\/i>. <i>Immunology<\/i>, <b>147<\/b>, 399\u2013413 (2016).","DOI":"10.1111\/imm.12570"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Takaishi M, Ishizaki M, Suzuki K, Isobe T, Shimozato T, Sano S. Oral administration of a novel ROR<i>\u03b3<\/i>t antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17. <i>J. Dermatol. Sci.<\/i>, <b>85<\/b>, 12\u201319 (2017).","DOI":"10.1016\/j.jdermsci.2016.10.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Arita K, Tao H, Crowe P, Thacher S, Otake S, Kobayashi K, Ebihara S, Okamoto Y, Katsuda Y, Yamaguchi T, Matsushita M. Pharmacological properties of JTE-151; a novel orally available ROR<i>\u03b3<\/i> antagonist that suppresses Th17 cell-related responses <i>in vitro<\/i> and <i>in vivo<\/i>. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 2050\u20132057 (2024).","DOI":"10.1248\/bpb.b24-00490"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. <i>Brain Behav. Immun.<\/i>, <b>24<\/b>, 641\u2013651 (2010).","DOI":"10.1016\/j.bbi.2010.01.014"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC, Becher B. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. <i>J. Immunol.<\/i>, <b>179<\/b>, 8098\u20138104 (2007).","DOI":"10.4049\/jimmunol.179.12.8098"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. <i>Nature<\/i>, <b>445<\/b>, 648\u2013651 (2007).","DOI":"10.1038\/nature05505"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, Gorman DM, Smith K, de Waal Malefyt R, Kastelein RA, McClanahan TK, Bowman EP. IL-23 stimulates epidermal hyperplasia <i>via<\/i> TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. <i>J. Exp. Med.<\/i>, <b>203<\/b>, 2577\u20132587 (2006).","DOI":"10.1084\/jem.20060244"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) van Cranenburgh OD, Smets EM, de Rie MA, Sprangers MA, de Korte JA. Web-based, educational, quality-of-life intervention for patients with a chronic skin disease: feasibility and acceptance in routine dermatological practice. <i>Acta Derm. Venereol.<\/i>, <b>95<\/b>, 51\u201356 (2015).","DOI":"10.2340\/00015555-1872"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. <i>J. Investig. Dermatol. Symp. Proc.<\/i>, <b>9<\/b>, 136\u2013139 (2004).","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. <i>J. Investig. Dermatol. Symp. Proc.<\/i>, <b>9<\/b>, 140\u2013147 (2004).","DOI":"10.1046\/j.1087-0024.2003.09110.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. <i>Br. J. Dermatol.<\/i>, <b>152<\/b>, 597\u2013615 (2005).","DOI":"10.1111\/j.1365-2133.2005.06563.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, Takaesu G, Hori S, Yoshimura A, Kobayashi T. Foxp3 inhibits ROR<i>\u03b3<\/i>t-mediated IL-17A mRNA transcription through direct interaction with ROR<i>\u03b3<\/i>t. <i>J. Biol. Chem.<\/i>, <b>283<\/b>, 17003\u201317008 (2008).","DOI":"10.1074\/jbc.M801286200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Tildrakizumab <i>versus<\/i> placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet<\/i>, <b>390<\/b>, 276\u2013288 (2017).","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ramirez JM, Brembilla NC, Sorg O, Chicheportiche R, Matthes T, Dayer JM, Saurat JH, Roosnek E, Chizzolini C. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. <i>Eur. J. Immunol.<\/i>, <b>40<\/b>, 2450\u20132459 (2010).","DOI":"10.1002\/eji.201040461"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Alam MS, Maekawa Y, Kitamura A, Tanigaki K, Yoshimoto T, Kishihara K, Yasutomo K. Notch signaling drives IL-22 secretion in CD4<sup>+<\/sup> T cells by stimulating the aryl hydrocarbon receptor. <i>Proc. Natl. Acad. Sci. U.S.A<\/i>, <b>107<\/b>, 5943\u20135948 (2010).","DOI":"10.1073\/pnas.0911755107"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. <i>J. Invest. Dermatol.<\/i>, <b>128<\/b>, 2625\u20132630 (2008).","DOI":"10.1038\/jid.2008.111"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Toda M, Leung DYM, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P, Fukuda T, Elias JA, Hamid QA. Polarized <i>in vivo<\/i> expression of IL-11 and IL-17 between acute and chronic skin lesions. <i>J. Allergy Clin. Immunol.<\/i>, <b>111<\/b>, 875\u2013881 (2003).","DOI":"10.1067\/mai.2003.1414"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Noda S, Su\u00e1rez-Fari\u00f1as M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, Peng X, Estrada YD, Nakajima S, Honda T, Shin JU, Lee H, Krueger JG, Lee KH, Kabashima K, Guttman-Yassky E. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased Th17 polarization. <i>J. Allergy Clin. Immunol.<\/i>, <b>136<\/b>, 1254\u20131264 (2015).","DOI":"10.1016\/j.jaci.2015.08.015"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Nakajima S, Kitoh A, Egawa G, Natsuaki Y, Nakamizo S, Moniaga CS, Otsuka A, Honda T, Hanakawa S, Amano W, Iwakura Y, Nakae S, Kubo M, Miyachi Y, Kabashima K. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. <i>J. Invest. Dermatol.<\/i>, <b>134<\/b>, 2122\u20132130 (2014).","DOI":"10.1038\/jid.2014.51"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Ewald DA, Noda S, Oliva M, Litman T, Nakajima S, Li X, Xu H, Workman CT, Scheipers P, Svitacheva N, Labuda T, Krueger JG, Su\u00e1rez-Fari\u00f1as M, Kabashima K, Guttman-Yassky E. Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. <i>J. Allergy Clin. Immunol.<\/i>, <b>139<\/b>, 562\u2013571 (2017).","DOI":"10.1016\/j.jaci.2016.08.029"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Han L, Yang J, Wang X, Li D, Lv L, Li B. Th17 cells in autoimmune diseases. <i>Front. Med.<\/i>, <b>9<\/b>, 10\u201319 (2015).","DOI":"10.1007\/s11684-015-0388-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. <i>Trends Mol. Med.<\/i>, <b>22<\/b>, 230\u2013241 (2016).","DOI":"10.1016\/j.molmed.2016.01.001"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. <i>Int. J. Inflamm.<\/i>, <b>2012<\/b>, 819467 (2012).","DOI":"10.1155\/2012\/819467"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A. Role of Th17 cells in human autoimmune arthritis. <i>Arthritis Rheum.<\/i>, <b>62<\/b>, 2876\u20132885 (2010).","DOI":"10.1002\/art.27622"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Penatti A, Facciotti F, De Matteis R, Larghi P, Paroni M, Murgo A, De Lucia O, Pagani M, Pierannunzii L, Truzzi M, Ioan-Facsinay A, Abrignani S, Geginat J, Meroni PL. Differences in serum and synovial CD4<sup>+<\/sup> T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis. <i>Arthritis Res. Ther.<\/i>, <b>19<\/b>, 103 (2017).","DOI":"10.1186\/s13075-017-1305-1"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, Dolhain RJ, Lubberts E. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. <i>Arthritis Rheum.<\/i>, <b>63<\/b>, 73\u201383 (2011).","DOI":"10.1002\/art.30093"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Matusevicius D, Kivis\u00e4kk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. <i>Mult. Scler.<\/i>, <b>5<\/b>, 101\u2013104 (1999).","DOI":"10.1177\/135245859900500206"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-<i>\u03b2<\/i>. <i>Ann. Neurol.<\/i>, <b>65<\/b>, 499\u2013509 (2009).","DOI":"10.1002\/ana.21652"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. <i>Am. J. Pathol.<\/i>, <b>172<\/b>, 146\u2013155 (2008).","DOI":"10.2353\/ajpath.2008.070690"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Hueber W, Patel DD, Dryja T, <i>et al<\/i>. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. <i>Sci. Transl. Med.<\/i>, <b>2<\/b>, 52ra72 (2010).","DOI":"10.1126\/scitranslmed.3001107"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. <i>J. Rheumatol.<\/i>, <b>41<\/b>, 414\u2013421 (2014).","DOI":"10.3899\/jrheum.130637"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. <i>Arthritis Rheumatol.<\/i>, <b>66<\/b>, 1693\u20131704 (2014).","DOI":"10.1002\/art.38617"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Havrdov\u00e1 E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, Garren H, Maguire RP, Johns DR. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. <i>J. Neurol.<\/i>, <b>263<\/b>, 1287\u20131295 (2016).","DOI":"10.1007\/s00415-016-8128-x"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00250\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T04:04:05Z","timestamp":1752897845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00250\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00250","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"b25-00250"}}